AFB/TB - XDR(EXTENSIVE DRUG RESISTANCE) DETECTION - HAINS GENOTYPING

AFB/TB - XDR (Extensively Drug Resistance) Detection by Hains Genotyping is an advanced molecular diagnostic test used to identify extensively drug-resistant tuberculosis (XDR-TB). This specialized assay detects genetic mutations associated with resistance to first-line and second-line anti-tuberculosis medications, enabling rapid diagnosis and appropriate treatment planning.

The test utilizes Hains Genotyping technology, a highly sensitive molecular method designed to identify drug resistance markers directly from clinical specimens or cultured isolates. Early detection of XDR-TB is essential for effective patient management, infection control, and prevention of disease transmission.

Benefits of the Test

• Rapid detection of extensively drug-resistant tuberculosis.
• Identifies resistance-associated genetic mutations.
• Supports early and targeted treatment decisions.
• Provides faster results than conventional culture methods.
• Helps prevent transmission of resistant TB strains.
• Improves patient management and clinical outcomes.
• Useful in treatment failure and recurrent TB cases.
• Highly sensitive molecular diagnostic technology.

Why Doctors Recommend This Test

Doctors recommend this test for patients with confirmed or suspected multidrug-resistant tuberculosis, treatment failure, recurrent TB, or known exposure to drug-resistant TB strains. The test helps identify resistance to multiple anti-tuberculosis drugs and guides individualized treatment planning.

Rapid resistance profiling is critical because delayed diagnosis can result in disease progression, treatment failure, and increased transmission of resistant organisms.

Preparation Before Test

• No fasting is required.
• Provide respiratory samples as instructed by the healthcare provider.
• Inform the doctor about previous TB treatment history.
• Ensure proper sample collection and transport.
• Follow laboratory instructions carefully.
• BAL or respiratory specimens should be collected by qualified professionals.

Normal Reporting Time

Most AFB/TB XDR Detection by Hains Genotyping reports at Focus Diagnostics are available within 2–3 hours after sample processing, depending on specimen quality and laboratory workflow.

Who Should Take This Test?

This test may be recommended for:

• Patients with multidrug-resistant tuberculosis.
• Individuals with treatment failure.
• People with recurrent tuberculosis infection.
• Patients exposed to XDR-TB cases.
• Individuals requiring second-line drug resistance testing.
• Patients with persistent TB symptoms despite treatment.
• High-risk tuberculosis patients.
• Patients undergoing advanced TB evaluation.

Detailed Information

Extensively drug-resistant tuberculosis (XDR-TB) represents one of the most challenging forms of tuberculosis because the causative bacteria develop resistance to multiple first-line and second-line anti-tuberculosis medications. Early identification of resistance patterns is essential for selecting effective therapies and reducing the spread of resistant strains.

Hains Genotyping is a molecular diagnostic technology designed to rapidly identify specific genetic mutations associated with drug resistance in Mycobacterium tuberculosis. Unlike traditional culture-based susceptibility testing, which may require several weeks, molecular testing can provide valuable information within a significantly shorter timeframe.

The test analyzes bacterial genetic material and detects mutations associated with resistance to important anti-tuberculosis drugs. This allows healthcare providers to understand resistance profiles and develop appropriate treatment strategies tailored to the patient’s condition.

XDR-TB patients often require specialized treatment regimens involving alternative medications, longer treatment durations, and close medical monitoring. Early diagnosis improves the likelihood of successful treatment while helping prevent disease transmission within communities and healthcare settings.

This test is particularly valuable in patients with recurrent tuberculosis, previous treatment failure, persistent symptoms, positive AFB findings, or known exposure to resistant TB strains. The information generated by Hains Genotyping supports infectious disease specialists, pulmonologists, microbiologists, and public health professionals in managing complex tuberculosis cases.

At Focus Diagnostics, AFB/TB XDR Detection by Hains Genotyping is performed using advanced molecular diagnostic platforms and stringent quality control standards to provide accurate, reliable, and clinically actionable results for tuberculosis management.